Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 7/2022

07-11-2021 | NSCLC | Original Article

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study

Authors: Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han, Tianqing Chu, Chunxia Su

Published in: Cancer Immunology, Immunotherapy | Issue 7/2022

Login to get access

Abstract

Background

Despite the remarkable clinical advance of immune checkpoint inhibitors (ICIs) in the treatment of lung cancer, there are limited studies focused on evaluating efficacy of ICIs for patients with human epidermal growth factor receptor 2 (HER2)-mutant lung adenocarcinoma.

Methods

We conducted a multicenter retrospective study of patients with HER2-mutant lung adenocarcinoma who received ICIs therapy at Shanghai Pulmonary Hospital, Shanghai Chest Hospital and the First Affiliated Hospital of Wenzhou Medical University between 2016 and 2021. Response was defined with reference to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

Results

Among the 26 patients enrolled in our study, the overall objective response rate (ORR) was 38.5%, disease control rate (DCR) was 84.6% and median progression-free survival (PFS) was 7.4 months. Majority of patients were treated with immunochemotherapy combination regimens (16/26, 61.5%), with a median PFS of 8.4 months. Among the 9 patients receiving ICIs-based therapy as first-line treatment, 5 patients had partial response (PR) and 4 patients had stable disease (SD), with a median PFS of 9.1 months. Of the entire cohort, 5 patients who received ICIs before epidermal growth factor receptor (EGFR)/HER2-targeting drugs achieved a median PFS of 8.4 months.

Conclusion

Our retrospective study provides clinical evidence that front line of ICIs-based therapy is also worth considering for the treatment to improve survival outcomes of patients with HER2-mutant lung adenocarcinoma.
Appendix
Available only for authorised users
Literature
1.
Zhou C, Wu Y-L, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742CrossRef
2.
Stephens P, Hunter C, Bignell G et al (2004) Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525–526CrossRef
3.
Sonobe M, Manabe T, Wada H et al (2006) Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. J Mol Diagn 8(3):351–356CrossRef
4.
Shigematsu H, Takahashi T, Nomura M et al (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642–1646CrossRef
5.
Pillai RN, Behera M, Berry LD et al (2017) HER2 mutations in lung adenocarcinomas: a report from the lung cancer mutation consortium. Cancer 123(21):4099–4105CrossRef
6.
Zhou C, Li X, Wang Q et al (2020) Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm. Phase II Study J Clin Oncol 38(24):1753–2761
7.
Tsurutani J, Iwata H, Krop I et al (2020) Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov 10(5):688–701CrossRef
8.
Mok. TSK, Wu. Y-L, Kudaba. I, et al., (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet, 393(1083): 1819–1830.
9.
Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833CrossRef
10.
Addeo A, Passaro A, Malapelle U et al (2021) Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev 96:102179CrossRef
11.
E.A. Eisenhauer PT, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, and R. Kaplan DL, J. Verweij, (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 45(2): 228-47
12.
Mazières J, Barlesi F, Filleron T et al (2016) Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 27(2):281–6CrossRef
13.
Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 30(8):1321–1328CrossRef
14.
Rolfo C, Russo A (2020) HER2 mutations in non-small cell lung cancer: a herculean effort to hit the target. Cancer Discov 10(5):643–645CrossRef
15.
Guisier F, Dubos-Arvis C, Vinas F et al (2020) Efficacy and Safety of Anti-PD-1 immunotherapy in patients with advanced NSCLC With BRAF, HER2, or MET mutations or RET translocation: GFPC 01–2018. J Thorac Oncol 15(4):628–636CrossRef
16.
Lau SCM, Fares AF, Le LW et al (2021) Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors. Clin Lung Cancer 22(4):253–259CrossRef
17.
Saalfeld FC, Wenzel C, Christopoulos P, et al., (2021) Brief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations. J Thorac Oncol,.
18.
Zhao S, Xian X, Tian P et al (2021) Efficacy of combination chemo-immunotherapy as a first-line treatment for advanced non-small-cell lung cancer patients with HER2 alterations: a case series. Front Oncol 11:633522CrossRef
19.
Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3(5):436–443CrossRef
20.
Huang MY, Jiang XM, Wang BL et al (2021) Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther 219:107694CrossRef
Metadata
Title
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study
Authors
Xiangling Chu
Huiping Qiang
Mengqing Xie
Xing Li
Jing Zhao
Yan Wu
Juan Zhou
Jinyan Ye
Chao Zhao
Chaonan Han
Tianqing Chu
Chunxia Su
Publication date
07-11-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 7/2022
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-021-03100-5

Other articles of this Issue 7/2022

Cancer Immunology, Immunotherapy 7/2022 Go to the issue

Original Article

Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells

Letter to the Editors

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy

Original Article

Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice

Original Article

Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study

Original Article

Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway

Original Article

Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits